logo
Sign in

VENATORX PHARMACEUTICALS INC

MALVERN, PA · Founded 2010 · Biotech · Defunct

Antibiotic molecules for bacterial infection treatment

Claim this profile

Follows are private to you and power your alerts

Updated · venatorx.com

Sector
Biotech
Headquarters
MALVERN, PA
Founded
2010
Latest Form D
$15M, Feb 2023
Total capital
$390M
Federal grants
$33M
41 awards · 2015–2025
Rank in peer group#326 of 514
Private capital raised
$87M
5 Form D · last Feb 2023
44 months since last filing
Federal contracts
$270M
5 awards · Health and Human S, Defense
Rank in Biotech#3 of 4373
Granted patents
27
13 pending · first 2019
Rank in peer group#4 of 514

Capital timeline

2013201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $390M2013: $28.2M across 1 contract$28.2M2015: $2.9M across 5 grants2016: $2.1M across 4 grants · $48.5M across 1 contract$50.6M2017: $5.8M across 5 grants · $14.3M across 1 contract$20.1M2018: $3.5M across 4 grants$3.5M2019: $3M across 3 grants · $107M across 1 contract$110M2020: $2.6M across 4 grants2021: $2.6M across 4 grants2022: $2M across 2 grants · $72.1M across 1 contract$74.1M2023: $3.3M across 4 grants2024: $3.3M across 4 grants2025: $2M across 2 grants1st Form D$3.4M2nd Form D$21.9M3rd Form D$34M5th Form D$15M
2013201720212025FEDERAL ↑EQUITY ↓Cumulative $390M2013: $28.2M across 1 contract$28.2M2015: $2.9M across 5 grants2016: $2.1M across 4 grants · $48.5M across 1 contract$50.6M2017: $5.8M across 5 grants · $14.3M across 1 contract2018: $3.5M across 4 grants2019: $3M across 3 grants · $107M across 1 contract$110M2020: $2.6M across 4 grants2021: $2.6M across 4 grants2022: $2M across 2 grants · $72.1M across 1 contract$74.1M2023: $3.3M across 4 grants2024: $3.3M across 4 grants2025: $2M across 2 grants2nd Form D$21.9M3rd Form D$34M5th Form D$15M

Latest events

  • Federal grantHealth and Human S · Phase II · Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections$1.0M
  • Federal grantHealth and Human S · Phase II · Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii$1M
  • Federal grantHealth and Human S · Phase I · Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections$300K
  • Federal grantHealth and Human S · Phase II · Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections$1M
  • Federal grantHealth and Human S · Phase II · Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii$1M
  • Federal grantHealth and Human S · Phase II · Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa$1M
  • Federal grantHealth and Human S · Phase I · Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections$300K
  • Private capital raisedForm D · SEC · 5th filing$15M
  • Private capital raisedForm D · SEC · 4th filing$12.7M
  • Private capital raisedForm D · SEC · 3rd filing$34M
  • Private capital raisedForm D · SEC · 2nd filing$21.9M
  • Private capital raisedForm D · SEC · 1st filing$3.4M
Show 39 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections$1M
  • Federal grantHealth and Human S · Phase II · Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection$1M
  • Federal grantHealth and Human S · Phase II · Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa$1M
  • Federal contractHealth and Human S · Venatorx Pharmaceuticals: Antibiotic For Amr And Biothreat Pathogens$72.1M
  • Federal grantHealth and Human S · Phase II · Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection$1M
  • Federal grantHealth and Human S · Phase II · Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa$1M
  • Federal grantHealth and Human S · Phase I · Discovery of inhibitors that target HBx for the treatment of chronic HBV infection$254K
  • Federal grantHealth and Human S · Phase I · Discovery of antiviral inhibitors of Ebola virus replication$300K
  • Federal grantHealth and Human S · Phase II · Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection$1M
  • Federal grantHealth and Human S · Phase II · Advancement of antiviral inhibitors of chikungunya virus$1M
  • Federal grantHealth and Human S · Phase I · Discovery of inhibitors that target HBx for the treatment of chronic HBV infection$253K
  • Federal grantHealth and Human S · Phase I · Discovery of antiviral inhibitors of Ebola virus replication$300K
  • Federal grantHealth and Human S · Phase II · Advancement of antiviral inhibitors of chikungunya virus$1M
  • Federal grantHealth and Human S · Phase II · Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$1M
  • Federal contractHealth and Human S · Venatorx Pharmaceuticals, Inc.$107M
  • Federal grantHealth and Human S · Phase II · Advancement to IND of novel BLI for pairing with cefixime$1M
  • Federal grantHealth and Human S · Phase II · Advancement of antiviral inhibitors of chikungunya virus$1M
  • Federal grantHealth and Human S · Phase II · Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$1M
  • Federal grantHealth and Human S · Phase II · Advancement to IND of novel BLI for pairing with cefixime$1M
  • Federal grantHealth and Human S · Phase II · Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series$1.2M
  • Federal grantHealth and Human S · Phase II · Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$1M
  • Federal grantHealth and Human S · Phase I · Discovery of inhibitors of Zika virus$300K
  • Federal contractDefense · Penicillin Binding Proteins Igf::ot::igf$14.3M
  • Federal grantHealth and Human S · Phase II · Advancement to IND of novel BLI for pairing with cefixime$1M
  • Federal grantHealth and Human S · Phase II · Advancement to IND of novel BLI for pairing with cefixime$3M
  • Federal grantHealth and Human S · Phase I · Discovery of inhibitors of BK polyomavirus$343K
  • Federal grantHealth and Human S · Phase II · Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series$1.2M
  • Federal grantHealth and Human S · Phase I · Discovery of inhibitors of Zika virus$300K
  • Federal contractHealth and Human S · Igf::ot::igf - Orally BIOAVAILABLEβ-LACTAM/β-LACTAMASE Inhibitor Combination For Biodefense And Public Health.$48.5M
  • Federal grantHealth and Human S · Phase II · Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series$1.1M
  • Federal grantHealth and Human S · Phase I · Discovery of inhibitors of BK polyomavirus$347K
  • Federal grantHealth and Human S · Phase I · Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$300K
  • Federal grantHealth and Human S · Phase I · Discovery and Advancement of Chikungunya virus inhibitors$300K
  • Federal grantHealth and Human S · Phase II · Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND$1M
  • Federal grantHealth and Human S · Phase II · Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase$1M
  • Federal grantHealth and Human S · Phase I · Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas$300K
  • Federal grantHealth and Human S · Phase I · Broad-spectrum, orally-bioavailable beta-lactamase inhibitors$300K
  • Federal grantHealth and Human S · Phase I · Discovery and Advancement of Chikungunya virus inhibitors$300K
  • Federal contractHealth and Human S · Igf::ot::igf Development Of Therapeutic Medical Countermeasures For Biodefense And Emerging Infectious Diseases$28.2M

Federal awards are summed by year (46 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

3months

from VENATORX PHARMACEUTICALS INC’s first federal award to its first private round.

First federal award · Sep 2013
Health and Human S · $28.2M
First Form D · Dec 2013
$3.4M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#4 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Christopher J. BurnsResearcherExecutive Officer, DirectorLinked by 3 patents
  • Daniel C. PevearResearcherExecutive OfficerLinked by $4.8M in grants as PI
  • Luigi J. XerriResearcherExecutive OfficerLinked by $4M in grants as PI
  • Anthony J MeehanExecutive OfficerNamed in SEC Form D filings
  • Carlo J. RizzutoDirectorNamed in SEC Form D filings
  • Ezra J. FelkerExecutive OfficerNamed in SEC Form D filings
Show all 16 people
  • James J. MurphyExecutive OfficerNamed in SEC Form D filings
  • Martin J. HeideckerDirectorNamed in SEC Form D filings
  • Michael C DiemDirectorNamed in SEC Form D filings
  • Sergei J. PetukhovDirectorNamed in SEC Form D filings
  • Shelley J. ChuDirectorNamed in SEC Form D filings
  • Tim J. HenkelExecutive OfficerNamed in SEC Form D filings
  • Timothy J. HainesDirectorNamed in SEC Form D filings
  • Timothy J. HenkelExecutive OfficerNamed in SEC Form D filings
  • Tomas C HeymanDirectorNamed in SEC Form D filings
  • Vincent J. MilanoDirectorNamed in SEC Form D filings

What it has protected

USPTO · 27 granted of 40
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .